| Literature DB >> 28930191 |
Nitin Shivappa1,2,3, Justyna Godos4, James R Hébert5,6,7, Michael D Wirth8,9,10, Gabriele Piuri11, Attilio F Speciani12, Giuseppe Grosso13,14.
Abstract
Diet and chronic inflammation of the colon have been suggested to be risk factors in the development of colorectal cancer (CRC). The possible link between inflammatory potential of diet, measured through the Dietary Inflammatory Index (DII®), and CRC has been investigated in several populations across the world. The aim of this study was to conduct a meta-analysis on studies exploring this association. Data from nine studies were eligible, of which five were case-control and four were cohort studies. Results from meta-analysis showed a positive association between increasing DII scores, indicating a pro-inflammatory diet, and CRC. Individuals in the highest versus the lowest (reference) DII category showed an overall 40% increased risk of CRC with moderate evidence of heterogeneity [relative risk (RR) = 1.40, 95% confidence interval (CI): 1.26, 1.55; I² = 69%, p < 0.001]. When analyzed as a continuous variable, results showed an increased risk of CRC of 7% for a 1-point increase in the DII score. Results remained unchanged when analyses were restricted to the four prospective studies. Results of our meta-analysis support the importance of adopting a healthier anti-inflammatory diet in preventing CRC. These results further substantiate the utility of DII as tool to characterize the inflammatory potential of diet and to predict CRC.Entities:
Keywords: colorectal cancer; cytokines; diet; dietary inflammatory index; epidemiology; inflammation; meta-analysis; nutrition
Mesh:
Year: 2017 PMID: 28930191 PMCID: PMC5622803 DOI: 10.3390/nu9091043
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow chart and process selection of relevant studies exploring the association between Dietary Inflammatory Index (DII) and risk of colorectal, colon and rectal cancer.
Characteristics of studies included in the meta-analysis.
| Author, Year | Study Design | Study Cohort, Country | Sex, Age Range/Mean (Years) | No. of Individuals/Controls | No. of Cases | Follow-Up (Years) | No. of Food Parameters to Calculate DII | Adjustments |
|---|---|---|---|---|---|---|---|---|
| Shivappa et al. 2014 [ | Cohort | Iowa Women’s Health Study, USA | Females, 62 ± 4 | 34,703 | 1636 | 19.6 | 37 | Age, BMI, smoking status, pack-years of smoking, education, hormone replacement therapy use, total energy intake, NSAIDs and history of diabetes. |
| Wirth et al. 2015 [ | Cohort | NIH-AARP, USA | Both males and females. | 489,422 | 6944 | 9.1 | 35 | Age, smoking status, BMI, self-reported diabetes, energy intake, physical activity, marital status, education, race and census-based income. |
| Harmon et al. 2017 [ | Cohort | Multiethnic Cohort | Both males and females. | 190,963 | 4388 | 20 | 28 | Age, sex, BMI, race, self-reported previous diagnosis of diabetes, asthma, and heart attack; use of supplements; smoking status; family history of colon cancer; education; hormone (i.e., estrogen or progesterone) use; aspirin use. |
| Tabung et al. 2015 [ | Cohort | Women’s Health Initiative, USA | Females. | 152,536 | 1920 | 11.3 | 32 | Age, total energy intake, body mass index, race/ethnicity, physical activity, educational level, smoking status, family history of colorectal cancer, hypertension, diabetes, arthritis, history of colonoscopy, history of occult blood tests, NSAID use, category and duration of estrogen use, category and duration of estrogen & progesterone use, dietary modification trial arm, hormone therapy trial arm and calcium and vitamin trial arm |
| Shivappa et al. 2015 [ | Case-control | Italy | Both males and females. | 4154 controls | 1953 | - | 31 | Age, sex, study center, education, BMI, alcohol consumption, physical activity, history of colorectal cancer, and energy intake |
| Zamora-Ros et al. 2015 [ | Case-control | Spain | Both males and females. | 401 controls | 424 | - | 33 | Age, sex, total energy intake, BMI, first-degree family history of CRC, physical activity, tobacco use, and medication use (aspirin and NSAID) |
| Cho et al. 2016 [ | Case-control | South Korea | Both males and females. | 1846 controls | 923 | - | 36 | Age, sex, BMI, education, family history of colorectal cancer, physical activity, and total energy intake. |
| Shivappa et al. 2017 [ | Case-control | Jordan | Both males and females. | 202 controls | 153 | - | 18 | Age, sex, education, physical activity, body mass index, smoking, and family history of colorectal cancer. |
| Sharma et al. 2017 [ | Case-control | Canada | Both males and females. | 685 controls | 547 | - | 29 | Age, sex, BMI, physical activity, cholesterol level, triglycerides, family history of CRC, polyps, diabetes, history of colon screening, smoking, alcohol consumption, regular use of NSAIDs, and reported HRT, females only. |
Figure 2Forest plot of summary relative risks (RRs) of colorectal cancer for the highest versus lowest (reference) category of Dietary Inflammatory Index (DII), for case-control, prospective and all studies.
Figure 3Funnel plots for colorectal cancer risk of the highest versus lowest (reference) category of Dietary Inflammatory Index (DII): (a) case-control, (b) prospective, and (c) all studies.
Subgroup analyses of studies reporting risk of colorectal, colon and rectal cancer for the highest versus lowest (reference) category of dietary inflammatory index (DII).
| Subgroup | No. of Datasets (No. of Studies) | RR (95% CI) | ||
|---|---|---|---|---|
| Colorectal | ||||
| Total | 13 (9) | 1.40 (1.26, 1.55) | 69% | 0.0001 |
| Study design | ||||
| Prospective | 6 (4) | 1.24 (1.15, 1.35) | 50% | 0.08 |
| Case-control | 7 (5) | 1.73 (1.46, 2.05) | 42% | 0.11 |
| Gender | ||||
| Men | 4 (4) | 1.51 (1.29, 1.75) | 68% | 0.02 |
| Women | 6 (6) | 1.25 (1.10, 1.41) | 61% | 0.02 |
| Geographical location | ||||
| North America | 7 (5) | 1.26 (1.16, 1.36) | 50% | 0.06 |
| Europe | 3 (2) | 1.57 (1.19, 2.07) | 61% | 0.08 |
| Asia | 3 (2) | 1.97 (1.57, 2.49) | 9% | 0.33 |
| Adjustment for smoking | ||||
| No | 4 (2) | 1.74 (1.34, 2.25) | 69% | 0.02 |
| Yes | 9 (7) | 1.28 (1.18, 1.40) | 52% | 0.03 |
| Adjustment for BMI | ||||
| No | 1 (1) | 1.65 (1.13, 2.42) | NA | NA |
| Yes | 12 (8) | 1.39 (1.25, 1.54) | 70% | 0.0001 |
| Adjustment for physical activity | ||||
| No | 3 (2) | 1.22 (1.12, 1.32) | 0% | 0.55 |
| Yes | 10 (7) | 1.51 (1.31, 1.74) | 70% | 0.0004 |
| Adjustment for NSAID | ||||
| No | 8 (5) | 1.50 (1.28, 1.75) | 76% | 0.0002 |
| Yes | 5 (4) | 1.25 (1.15, 1.37) | 21% | 0.28 |
| Colon | ||||
| Total | 10 (7) | 1.38 (1.23, 1.55) | 61% | 0.006 |
| Study design | ||||
| Prospective | 5 (4) | 1.25 (1.16, 1.35) | 11% | 0.34 |
| Case-control | 5 (3) | 1.70 (1.29, 2.24) | 62% | 0.03 |
| Gender | ||||
| Men | 3 (3) | 1.58 (1.36, 1.83) | 0% | 0.71 |
| Women | 5 (5) | 1.27 (1.10, 1.48) | 51% | 0.09 |
| Geographical location | ||||
| North America | 5 (4) | 1.25 (1.16, 1.35) | 11% | 0.34 |
| Europe | 3 (2) | 1.56 (1.06, 2.29) | 71% | 0.03 |
| Asia | 2 (1) | 1.97 (1.34, 2.90) | 39% | 0.20 |
| Adjustment for smoking | ||||
| No | 4 (2) | 1.62 (1.20, 2.19) | 66% | 0.03 |
| Yes | 6 (5) | 1.29 (1.16, 1.43) | 46% | 0.10 |
| Adjustment for BMI | ||||
| No | 0 (0) | NA | NA | NA |
| Yes | 10 (7) | 1.38 (1.23, 1.55) | 61% | 0.006 |
| Adjustment for physical activity | ||||
| No | 2 (2) | 1.20 (1.10, 1.31) | 0% | 0.94 |
| Yes | 8 (5) | 1.48 (1.27, 1.72) | 59% | 0.02 |
| Adjustment for NSAID | ||||
| No | 7 (4) | 1.43 (1.23, 1.66) | 58% | 0.03 |
| Yes | 3 (3) | 1.29 (1.07, 1.56) | 62% | 0.07 |
| Rectal | ||||
| Total | 10 (7) | 1.35 (1.18, 1.56) | 48% | 0.04 |
| Study design | ||||
| Prospective | 5 (4) | 1.23 (1.03, 1.47) | 54% | 0.07 |
| Case-control | 5 (3) | 1.55 (1.30, 1.85) | 7% | 0.36 |
| Gender | ||||
| Men | 3 (3) | 1.56 (1.35, 1.81) | 0% | 0.75 |
| Women | 5 (5) | 1.28 (0.97, 1.69) | 59% | 0.05 |
| Geographical location | ||||
| North America | 5 (4) | 1.23 (1.03, 1.47) | 54% | 0.07 |
| Europe | 3 (2) | 1.41 (1.15, 1.73) | 0% | 0.72 |
| Asia | 2 (1) | 1.90 (1.41, 2.56) | 3% | 0.31 |
| Adjustment for smoking | ||||
| No | 4 (2) | 1.60 (1.34, 1.91) | 4% | 0.37 |
| Yes | 6 (5) | 1.22 (1.04, 1.44) | 43% | 0.12 |
| Adjustment for BMI | ||||
| No | 0 (0) | NA | NA | NA |
| Yes | 10 (7) | 1.35 (1.18, 1.56) | 48% | 0.04 |
| Adjustment for physical activity | ||||
| No | 2 (2) | 1.22 (1.03, 1.43) | 0% | 0.97 |
| Yes | 8 (5) | 1.40 (1.17, 1.68) | 54% | 0.03 |
| Adjustment for NSAID | ||||
| No | 7 (4) | 1.43 (1.18, 1.73) | 58% | 0.03 |
| Yes | 3 (3) | 1.21 (1.04, 1.41) | 0% | 0.96 |
Figure 4Forest plot of summary relative risks (RRs) of colorectal cancer for a one-point increase of Dietary Inflammatory Index (DII), for case-control, prospective and all studies.
Figure 5Funnel plots for colorectal cancer risk of a one-point increase of Dietary Inflammatory Index (DII): (a) case-control, (b) prospective, and (c) total studies.
Figure 6Forest plot of summary relative risks (RRs) of colon and rectal cancer for the highest versus lowest (reference) category of Dietary Inflammatory Index (DII).
Figure 7Funnel plots for colon and rectal cancer risk of the highest versus lowest (reference) category of Dietary Inflammatory Index (DII): (a) colon and (b) rectal.